Cargando…
Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle
Dry eye disease (DED) impacts ≈30% of the world's population and causes serious ocular discomfort and even visual impairment. Inflammation is one core cause of the DED vicious cycle, a multifactorial deterioration in DED process. However, there are also reactive oxygen species (ROS) regulating...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189644/ https://www.ncbi.nlm.nih.gov/pubmed/35435328 http://dx.doi.org/10.1002/advs.202200435 |
_version_ | 1784725632019595264 |
---|---|
author | Li, Su Lu, Zhouyu Huang, Yue Wang, Yin Jin, Qiao Shentu, Xingchao Ye, Juan Ji, Jian Yao, Ke Han, Haijie |
author_facet | Li, Su Lu, Zhouyu Huang, Yue Wang, Yin Jin, Qiao Shentu, Xingchao Ye, Juan Ji, Jian Yao, Ke Han, Haijie |
author_sort | Li, Su |
collection | PubMed |
description | Dry eye disease (DED) impacts ≈30% of the world's population and causes serious ocular discomfort and even visual impairment. Inflammation is one core cause of the DED vicious cycle, a multifactorial deterioration in DED process. However, there are also reactive oxygen species (ROS) regulating inflammation and other points in the cycle from the upstream, leading to treatment failure of current therapies merely targeting inflammation. Accordingly, the authors develop micelle‐based eye drops (more specifically p38 mitogen‐activated protein kinases (MAPK) inhibitor Losmapimod (Los)‐loaded and ROS scavenger Tempo (Tem)‐conjugated cationic polypeptide micelles, designated as MTem/Los) for safe and efficient DED management. Cationic MTem/Los improve ocular retention of conjugated water‐soluble Tem and loaded water‐insoluble Los via electrostatic interaction with negatively charged mucin on the cornea, enabling an increase in therapeutic efficiency and a decrease in dosing frequency. Mechanistically, MTem/Los effectively decrease ROS over‐production, reduce the expression of proinflammatory cytokines and chemokines, restrain macrophage proinflammatory phenotypic transformation, and inhibit cell apoptosis. Therapeutically, the dual‐functional MTem/Los suppress the inflammatory response, reverse corneal epithelial defect, save goblet cell dysfunction, and recover tear secretion, thus breaking the vicious cycle and alleviating the DED. Moreover, MTem/Los exhibit excellent biocompatibility and tolerability for potential application as a simple and rapid treatment of oxidative stress‐ and inflammation‐induced disorders, including DED. |
format | Online Article Text |
id | pubmed-9189644 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91896442022-06-16 Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle Li, Su Lu, Zhouyu Huang, Yue Wang, Yin Jin, Qiao Shentu, Xingchao Ye, Juan Ji, Jian Yao, Ke Han, Haijie Adv Sci (Weinh) Research Articles Dry eye disease (DED) impacts ≈30% of the world's population and causes serious ocular discomfort and even visual impairment. Inflammation is one core cause of the DED vicious cycle, a multifactorial deterioration in DED process. However, there are also reactive oxygen species (ROS) regulating inflammation and other points in the cycle from the upstream, leading to treatment failure of current therapies merely targeting inflammation. Accordingly, the authors develop micelle‐based eye drops (more specifically p38 mitogen‐activated protein kinases (MAPK) inhibitor Losmapimod (Los)‐loaded and ROS scavenger Tempo (Tem)‐conjugated cationic polypeptide micelles, designated as MTem/Los) for safe and efficient DED management. Cationic MTem/Los improve ocular retention of conjugated water‐soluble Tem and loaded water‐insoluble Los via electrostatic interaction with negatively charged mucin on the cornea, enabling an increase in therapeutic efficiency and a decrease in dosing frequency. Mechanistically, MTem/Los effectively decrease ROS over‐production, reduce the expression of proinflammatory cytokines and chemokines, restrain macrophage proinflammatory phenotypic transformation, and inhibit cell apoptosis. Therapeutically, the dual‐functional MTem/Los suppress the inflammatory response, reverse corneal epithelial defect, save goblet cell dysfunction, and recover tear secretion, thus breaking the vicious cycle and alleviating the DED. Moreover, MTem/Los exhibit excellent biocompatibility and tolerability for potential application as a simple and rapid treatment of oxidative stress‐ and inflammation‐induced disorders, including DED. John Wiley and Sons Inc. 2022-04-18 /pmc/articles/PMC9189644/ /pubmed/35435328 http://dx.doi.org/10.1002/advs.202200435 Text en © 2022 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Li, Su Lu, Zhouyu Huang, Yue Wang, Yin Jin, Qiao Shentu, Xingchao Ye, Juan Ji, Jian Yao, Ke Han, Haijie Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle |
title | Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle |
title_full | Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle |
title_fullStr | Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle |
title_full_unstemmed | Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle |
title_short | Anti‐Oxidative and Anti‐Inflammatory Micelles: Break the Dry Eye Vicious Cycle |
title_sort | anti‐oxidative and anti‐inflammatory micelles: break the dry eye vicious cycle |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189644/ https://www.ncbi.nlm.nih.gov/pubmed/35435328 http://dx.doi.org/10.1002/advs.202200435 |
work_keys_str_mv | AT lisu antioxidativeandantiinflammatorymicellesbreakthedryeyeviciouscycle AT luzhouyu antioxidativeandantiinflammatorymicellesbreakthedryeyeviciouscycle AT huangyue antioxidativeandantiinflammatorymicellesbreakthedryeyeviciouscycle AT wangyin antioxidativeandantiinflammatorymicellesbreakthedryeyeviciouscycle AT jinqiao antioxidativeandantiinflammatorymicellesbreakthedryeyeviciouscycle AT shentuxingchao antioxidativeandantiinflammatorymicellesbreakthedryeyeviciouscycle AT yejuan antioxidativeandantiinflammatorymicellesbreakthedryeyeviciouscycle AT jijian antioxidativeandantiinflammatorymicellesbreakthedryeyeviciouscycle AT yaoke antioxidativeandantiinflammatorymicellesbreakthedryeyeviciouscycle AT hanhaijie antioxidativeandantiinflammatorymicellesbreakthedryeyeviciouscycle |